Welcome to our dedicated page for Sonoma Pharmaceuticals SEC filings (Ticker: SNOA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sonoma Pharmaceuticals filings document the regulatory record for a Nasdaq-listed healthcare company with common stock trading under SNOA. Its disclosures include Securities Act registration statements, current reports on material events, proxy materials for shareholder voting matters, and common-stock and capital-structure information.
Recent filings cover material agreements involving Microcyn technology-based products, governance and executive or director changes, investor presentation materials, and proxy items related to corporate organization and stockholder approval mechanics. Registration statements and amendments describe offered securities, reporting-company status and related disclosure controls, while 8-K reports record definitive agreements, leadership matters and other company events affecting Sonoma’s operations and governance.
Sonoma Pharmaceuticals, Inc. (SNOA) reports that an adjourned special meeting of stockholders scheduled for August 19, 2026 was cancelled. As of the April 28, 2026 record date, 3,473,554 shares of common stock were entitled to vote, and a quorum required the presence in person or by proxy of 1,157,852 shares, representing one-third of the outstanding shares. A quorum was not present, so the chairman cancelled the special meeting, and the company states it will not solicit additional proxies for this meeting.
Sonoma Pharmaceuticals reported strong improvement for the quarter ended June 30, 2026. Revenue rose to $6,406,000, up from $4,015,000 a year earlier, a 60% increase, with 141% growth in the United States and double‑digit gains across Europe, Asia, Latin America and other regions. Gross profit increased to $2,577,000 and gross margin expanded to 40% from 36%.
The company narrowed its net loss to $330,000, or $0.09 per share, from $1,241,000, as research and development and selling, general and administrative costs grew only modestly. Operating cash outflow improved to $649,000 from $2,015,000. Equity issuance, including an underwritten unit offering and at‑the‑market sales, generated $3,536,000 of net proceeds, lifting cash to $5,338,000 and working capital to $10,821,000; management believes this, together with existing resources, will fund projected needs for at least twelve months.
Common shares outstanding increased sharply to 4,785,801, and 3,407,404 new warrants to purchase common stock were issued, creating meaningful potential dilution. The company also discloses sizable Mexico intercompany loans, accrued interest and related tax and withholding exposures, and notes new Nasdaq Market Value of Listed Securities requirements that could heighten delisting risk if thresholds are not met.
Sonoma Pharmaceuticals is soliciting proxies for its 2026 Annual Meeting on September 16, 2026 at 2:00 p.m. MDT at its Boulder, Colorado office. Stockholders of record at the close of business on July 24, 2026, when 4,788,425 shares of common stock were outstanding, may vote.
Stockholders are asked to elect one Class III director (Jerry McLaughlin), approve on an advisory basis 2026 executive compensation, ratify Frazier & Deeter, LLC as auditor for fiscal 2027, and authorize possible adjournment to solicit additional proxies. The filing details a classified, majority-independent board, committee structure, and director pay.
For fiscal 2026, CEO Amy Trombly received total compensation of $741,116, and CFO Jerry Dvonch received $422,679, combining salary, cash bonuses and equity. An amended CEO employment agreement provides base salary of $475,000, a 50% target bonus and significant severance and change-of-control protections. Pay-versus-performance disclosure shows 2026 “compensation actually paid” versus a net loss of $3,175 thousand and a total shareholder return value of $10.91 on an initial $100 investment.
Sonoma Pharmaceuticals, Inc. director Philippe Weigerstorfer received a grant of stock options for 10,000 shares of common stock at an exercise price of $1.2600 per share. The options vest in three equal installments on July 9, 2027, July 9, 2028, and July 9, 2029, or upon a change of control. Following this award, he holds 30,001 stock options directly, expiring on July 9, 2036, as compensation for his Board service.
Trombly Amy Moss reported acquisition or exercise transactions in this Form 4 filing.
Sonoma Pharmaceuticals, Inc. reported that Chief Executive Officer Amy Moss Trombly received a grant of 10,000 Restricted Stock Units (RSUs), each representing a contingent right to receive one share of common stock. The RSUs vest on the third anniversary of the grant date or upon a change of control. Following this award, she holds 52,185 RSUs directly.
Sonoma Pharmaceuticals, Inc. director John McLaughlin received a grant of stock options for 10,000 shares of common stock at an exercise price of $1.26 per share. The options vest in three equal installments on July 9, 2027, July 9, 2028, and July 9, 2029, or upon a change of control. Following this award, he holds stock options covering 30,001 shares directly.
Sonoma Pharmaceuticals director Vanessa Jacoby received a grant of stock options. She was awarded options to acquire 10,000 shares of common stock at an exercise price of $1.26 per share for Board service. The options vest one-third each on July 9, 2027, July 9, 2028, and July 9, 2029, or upon a change of control, and expire on July 9, 2036. Following this grant, she holds 20,000 derivative option shares in total.
DVONCH JEROME J reported acquisition or exercise transactions in this Form 4 filing.
Sonoma Pharmaceuticals, Inc. reported that its Chief Financial Officer, Jerome J. Dvonch, received a grant of 10,000 Restricted Stock Units representing contingent rights to an equal number of common shares. Following this award, he holds 44,391 shares-related units directly. Footnotes state each RSU equals one share of common stock and reference the third anniversary of the grant date or a change of control.
Dal Poggetto John reported acquisition or exercise transactions in this Form 4 filing.
Sonoma Pharmaceuticals, Inc. reported that Controller John Dal Poggetto received a grant of 7,500 Restricted Stock Units (RSUs), each representing a contingent right to one share of common stock. The RSUs vest on the third anniversary of the grant date or upon a change of control. Following this award, Dal Poggetto holds 32,750 RSUs directly, with no shares bought or sold in the market as part of this filing.
Sonoma Pharmaceuticals updated investors on its at-the-market stock offering program with Ladenburg Thalmann. The company originally registered up to $2,070,463 of common stock under a Form S-3 shelf and related prospectus supplement. From September 26, 2025 through June 18, 2026, it sold 173,073 shares for an aggregate purchase price of $574,633 under this agreement. As of June 18, 2026, the amount of common stock it may offer pursuant to General Instruction I.B.6 of Form S-3 has increased to an aggregate offering price of $3,641,703, and Sonoma filed a supplement to the prospectus supplement to increase the aggregate offering price to this level, including the $1,495,830 shares of common stock that were previously registered and not sold to date.